Becton, Dickinson and Company (BDX) News
Follow Becton, Dickinson and Company (BDX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 60 public stories across 32 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Becton Dickinson and Cardinal Health Beat Quarterly Views
Becton Dickinson and Cardinal Health reported quarterly results that beat views.
EARNINGS | Nov 05, 2026, 06:04 PM UTC
M
Becton Dickinson Expects Fiscal 2027 Adjusted EPS of $13.10–$13.30
Becton Dickinson expects fiscal 2027 adjusted EPS of $13.10 to $13.30, versus a FactSet estimate of $13.25.
EARNINGS | Nov 05, 2026, 11:56 AM UTC
M
Becton Dickinson Q4 revenue reaches USD 5,274 million
Becton Dickinson reported Q4 revenue of USD 5,274 million, compared with an IBES estimate of USD 5,113 million.
EQUITY | Nov 05, 2026, 11:54 AM UTC
M
Becton Dickinson Fiscal Q4 Earnings Snapshot
EQUITY | Nov 05, 2026, 11:50 AM UTC
M
Becton Dickinson shares fall 3.2% premarket after Q4 results
EQUITY | Nov 05, 2026, 11:43 AM UTC
M
Becton Dickinson Expects FY2026 Adjusted EPS of $13.10–$13.30
The company expects fiscal 2026 adjusted EPS of $13.10 to $13.30, versus a FactSet estimate of $12.67.
EARNINGS | Nov 05, 2026, 11:41 AM UTC
M
Becton Dickinson Q4 Revenue Beats Estimates on Broad-Based Growth
EQUITY | Nov 05, 2026, 11:39 AM UTC
M
BD Adjusted Q4 FY26 EPS Rises 27%
BD reported adjusted EPS for Q4 FY26, up 27%.
EARNINGS | Nov 05, 2026, 11:39 AM UTC
L
Becton Dickinson Sees FY27 Revenue Up Low-Single Digits
EARNINGS | Nov 05, 2026, 11:36 AM UTC
M
Becton Dickinson Sees FY Adjusted EPS of $13.10-$13.30
The outlook range compares with an IBES estimate of $13.30.
EARNINGS | Nov 05, 2026, 11:33 AM UTC
M
Becton Dickinson Q4 Adjusted EPS $4.15 vs. IBES Estimate $4.07
EARNINGS | Nov 05, 2026, 11:33 AM UTC
L
Becton Dickinson Reports Q4 EPS of $2.52
EARNINGS | Nov 05, 2026, 11:32 AM UTC
M
BD Reports Fourth-Quarter and Full-Year Fiscal 2026 Results
BD reported fourth-quarter revenue of $5.3 billion, up 5.4% as reported and 5.6% on an FX-neutral basis. The supplied body cuts off before reporting diluted EPS figures.
EQUITY | Nov 05, 2026, 11:30 AM UTC
M
Becton Dickinson Q4'26 Earnings Preview
Becton Dickinson is set to report Q4'26 results November 05 before the market opens. Revenue and EPS estimates are provided in the source.
EQUITY | Nov 04, 2026, 12:01 PM UTC
M
Becton Dickinson Q4 earnings preview
Becton, Dickinson and Company is scheduled to report Q4'26 results on November 05 before the market opens. Revenue and EPS estimates were provided.
EQUITY | Oct 29, 2026, 11:01 AM UTC
M
Jury Awards $40 Million in Bard Implanted Port Catheter Bellwether Verdict
A jury awarded $40 million to a plaintiff in a bellwether verdict in litigation over Bard implanted port catheters.
REGULATION | Oct 28, 2026, 09:41 PM UTC
M
BD to announce fourth-quarter and full-year fiscal 2026 results
EQUITY | Oct 08, 2026, 08:15 PM UTC
M
Becton Dickinson CEO expects U.S. expansion to ease hospital shortages
Becton Dickinson CEO Tom Polen said the company’s $3 billion plan to expand U.S. manufacturing aims to strengthen hospital supply chains.
EQUITY | Oct 07, 2026, 05:00 PM UTC
M
Budimex selected for Czech D35 motorway PPP consortium
Budimex was chosen as part of a consortium for the Czech D35 motorway PPP project, per TradingView News.
MNA | Oct 06, 2026, 12:31 PM UTC
M
Becton Dickinson Pledges $19B U.S. Investment for Tariff Relief
Becton Dickinson has agreed to invest $19 billion in the United States in exchange for relief from future tariffs, according to a deal with the Trump administration. This makes the medical device maker the latest company
EQUITY | Oct 06, 2026, 12:26 PM UTC
H
Becton, Dickinson to Invest $19 Bln in Domestic Manufacturing Partnership with U.S. Govt.
Becton, Dickinson and Co. (BDX) announced a long-term partnership with the U.S. Government to expand domestic manufacturing and enhance supply chain resilience for essential medical consumables. The company will invest $
EQUITY | Oct 06, 2026, 11:51 AM UTC
H
Becton Dickinson Agrees to Invest $19B in US for Tariff Relief
Becton Dickinson has reached an agreement with the Trump administration to expand domestic manufacturing in exchange for relief from future tariffs. The medical technology company committed to investing $19 billion in th
EQUITY | Oct 06, 2026, 11:30 AM UTC
M
Becton Dickinson to invest $19 billion in US
Becton Dickinson plans to invest $19 billion in the United States over several years, including $3 billion to expand domestic manufacturing, as part of an agreement with the US government.
EQUITY | Oct 06, 2026, 10:41 AM UTC
H
Trump Says Becton Dickinson to Invest $3 Billion in US Manufacturing as 'Strong' Medical Device Tariffs Loom by Year-End
Becton Dickinson and Co. (NYSE: BDX ) plans to invest $3 billion in U.S. medical-product manufacturing, President Donald Trump said. In a Truth Social post late Monday, Trump said that more than $1 billion will be invest
LIVE | Oct 06, 2026, 09:26 AM UTC
H
Becton Dickinson Q3 2026 Earnings Call: Complete Transcript
Becton Dickinson (NYSE: BDX ) held its third-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered APIs. For comprehensive financial data and transcripts, v
LIVE | Oct 05, 2026, 10:35 AM UTC
L
Budimex Offer For Czajka Wastewater Treatment Plant Modernisation Rejected
Budimex SA GPW:BDX:Source text for Workspace:Further company coverage
NEWS | Sep 28, 2026, 05:28 AM UTC
L
BCAL Diagnostic Commences Phased Australian Rollout of Avantect Multi-Cancer Blood Test
BCAL Diagnostics ASX:BDX has commenced the phased Australian market rollout of the Avantect blood-based test for the non-invasive detection of cancer-associated signals across multiple cancer types.Initial distribution w
NEWS | Sep 23, 2026, 04:42 AM UTC
L
BCAL Diagnostics Introduces Avantect Multi-Cancer Early Detection Test
BCAL Diagnostics Ltd ASX:BDX
NEWS | Sep 23, 2026, 01:28 AM UTC
L
BDX - Arthur Hu to Join BD as Chief Information and Digital Officer
BDX - Arthur Hu to Join BD as Chief Information and Digital Officer
NEWS | Sep 21, 2026, 08:30 PM UTC
L
BCAL Diagnostics Clarifies Of Bcal's Position In Relation To Genetic Signatures
BCAL Diagnostics Ltd ASX:BDX
EQUITY | Sep 10, 2026, 07:52 AM UTC
L
BDX: Growth platforms drive strong results as headwinds ease and innovation accelerates
Management highlighted strong growth from focused platforms, ongoing margin expansion, and disciplined pricing. Key headwinds from Alaris, vaccines, and China are expected to ease, while innovation and capital allocation
GEOPOLITICS | Sep 09, 2026, 03:09 PM UTC
L
Budimex announces annulment of offer selection for bypass project
Budimex SA notified about annulment of offer selection for the design and construction of the Brzostek and Kołaczyce bypass.
EQUITY | Sep 07, 2026, 03:01 PM UTC
L
Genetic Signatures Requested BCAL Diagnostics To Clarify Details Of Shareholdings, Associates In Co
Genetic Signatures Requested BCAL Diagnostics To Clarify Details Of Shareholdings, Associates In Co
EQUITY | Sep 02, 2026, 11:45 PM UTC
L
Becton Dickinson price target raised by B of A Securities
B of A Securities raised its Becton Dickinson price target to $200.00/share from $185.00.
EQUITY | Aug 31, 2026, 05:49 PM UTC
L
Budimex 195.5 million zloty offer selected in PSE tender
PSE selected Budimex’s 195.5 million zloty offer as the most favourable in a tender.
EQUITY | Aug 28, 2026, 03:21 PM UTC
L
BDX - BD Extends Leadership in Advanced Tissue Regeneration Through Continued Clinical Innovation
BDX - BD Extends Leadership in Advanced Tissue Regeneration Through Continued Clinical Innovation
EQUITY | Aug 27, 2026, 10:50 AM UTC
L
BDX - BD to Present at Wells Fargo 21st Annual Healthcare Conference
BDX - BD to Present at Wells Fargo 21st Annual Healthcare Conference
EQUITY | Aug 26, 2026, 08:15 PM UTC
L
BD to Present at Wells Fargo 21st Annual Healthcare Conference
BD to Present at Wells Fargo 21st Annual Healthcare Conference
EQUITY | Aug 26, 2026, 08:15 PM UTC
H
BDX: US FDA early alert flags high-risk issue in convenience kits
Becton Dickinson says the US FDA issued an early alert regarding a high-risk issue with its convenience kits and advises removing recalled components and avoiding sodium chloride ampules in affected kits.
REGULATION | Aug 18, 2026, 08:25 PM UTC
M
BDX appoints Gary Sorsher as Chief Quality Officer
BD appoints Gary Sorsher as Chief Quality Officer and names Jeff Silvestri to retire, according to TradeXchange Newsdesk.
REGULATION | Aug 17, 2026, 08:30 PM UTC
H
FDA alerts providers on Medline kits tied to BD recall
The FDA alerted healthcare providers about Medline convenience kits containing recalled Becton Dickinson antiseptic applicators, and Medline instructed customers to inspect and quarantine affected stock.
EARNINGS | Aug 13, 2026, 06:00 PM UTC
L
BDX - BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
BDX - BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
EQUITY | Aug 12, 2026, 10:50 AM UTC
H
Becton Dickinson Q3 Adjusted EPS Beats Estimates
Becton Dickinson reports Q3 adjusted EPS of $3.23
EARNINGS | Aug 06, 2026, 10:41 AM UTC
H
Becton Dickinson Raises FY2026 Adj EPS Guidance from $12.52-$12.72 to $12.62-$12.72 vs $12.61 Est
Becton Dickinson (NYSE: BDX ) raises FY2026 Adj EPS guidance from $12.52-$12.72 to $12.62-$12.72 vs $12.61 analyst estimate..
EARNINGS | Aug 06, 2026, 10:31 AM UTC
L
BDX - BD Reports Third Quarter Fiscal 2026 Financial Results
BDX - BD Reports Third Quarter Fiscal 2026 Financial Results
EQUITY | Aug 06, 2026, 10:30 AM UTC
M
BDX: Recall Does Not Affect Intraosseous Driver
BDX recall does not affect intraosseous driver
EQUITY | Jul 31, 2026, 06:32 PM UTC
H
BDX: 4 deaths reported from defective needle sets
BDX faces complaints over defective needle sets
EQUITY | Jul 31, 2026, 06:31 PM UTC
H
BDX Reports Stylet Removal Issues
BDX reports 4 deaths due to stylet removal issues
EQUITY | Jul 31, 2026, 06:30 PM UTC
H
BDX Recalls Vascular Access System Needle Sets
BDX recalls needle sets due to difficulty removing obturator
EQUITY | Jul 31, 2026, 06:30 PM UTC
H
BDX launches semaglutide in Brazil
BDX expands GLP-1 therapies in Brazil
EQUITY | Jul 29, 2026, 10:55 AM UTC
H
Intuit downgrade, Intuitive Surgical upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled. Top 5 Upgrades: UBS upgraded Intuitive Surgical (I
EARNINGS | Jul 28, 2026, 01:35 PM UTC
L
BDX new Buy W/ $190 PT @ UBS
BDX new Buy W/ $190 PT @ UBS
EQUITY | Jul 28, 2026, 12:43 PM UTC
L
BDX Initiated Buy W/$190.00 PT at UBS
BDX Initiated Buy W/$190.00 PT at UBS
EQUITY | Jul 28, 2026, 11:49 AM UTC
L
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: O
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: OUTPERFORM @ Wedbush CRWD: BUY @ Loop FTH: OUTPERFORM @ Opp HRB: EQUAL WEIGHT @ S
EQUITY | Jul 28, 2026, 11:11 AM UTC
L
Near 200dma support AWK NI NEE BDX FAST BLK PG WAL ITT MCK WTRG BRKB ATO DKS
Near 200dma support AWK NI NEE BDX FAST BLK PG WAL ITT MCK WTRG BRKB ATO DKS
EQUITY | Jul 20, 2026, 04:42 PM UTC
L
Outperformers vs S&P sector ETFs (% chg vs ETF) Consumer Discretionary (XLY) - BKNG +2.50%, RCL +2.37%, TPR +2.29%, AMZN +1.89%, ROST +1.53%
Outperformers vs S&P sector ETFs (% chg vs ETF) Consumer Discretionary (XLY) - BKNG +2.50%, RCL +2.37%, TPR +2.29%, AMZN +1.89%, ROST +1.53% Consumer Staples (XLP) - TGT +2.73%, CLX +2.53%, DLTR +2.24%, PM +1.82%, EL +1.
RATES | Jul 15, 2026, 06:23 PM UTC
L
BDX REGN SJM session highs
BDX REGN SJM session highs
EQUITY | Jul 14, 2026, 05:13 PM UTC
L
BDX Price Target Alert: $180.00. Issued by Evercore ISI
2026-07-06 10:15:13 ET from Evercore ISI issued a price target of $180.00 for BDX on 2026-07-06 12:40:26. <
EQUITY | Jul 06, 2026, 02:15 PM UTC
L
Evercore ISI Adjusts Price Target on Becton, Dickinson and Company to $180 From $190
() -- Becton, Dickinson and Company (BDX) has an average rating of overweight and mean price target of $172.55, according to analysts polled by FactSet. ( covers equity, commodity and economic research from major banks a
EQUITY | Jul 06, 2026, 01:21 PM UTC
L
BDX Awarded Contract
BDX awarded Vizient Innovative Technology Contract for CentroVena One Insertion System
EQUITY | Jun 23, 2026, 10:51 AM UTC